# Matrix metalloproteinases and their tissue inhibitors after selective laser trabeculoplasty in pseudoexfoliative secondary glaucoma

Submission date Recruitment status Prospectively registered 13/03/2008 No longer recruiting [ ] Protocol [ ] Statistical analysis plan Registration date Overall study status 20/03/2008 Completed [X] Results [ ] Individual participant data Last Edited Condition category 30/12/2020 **Eve Diseases** 

# Plain English summary of protocol

Not provided at time of registration

# Contact information

## Type(s)

Scientific

#### Contact name

Dr Mauro Cellini

#### Contact details

Via Massarenti, 9 Bologna Italy 40138

# Additional identifiers

Protocol serial number N/A

# Study information

#### Scientific Title

Matrix metalloproteinases and their tissue inhibitors after selective laser trabeculoplasty in pseudoexfoliative secondary glaucoma

# Study objectives

Pseudoexfoliative glaucoma (PEXG) is a degenerative fibrillopathy characterised by the production and accumulation of extracellular fibrillar material not just in the anterior segment of the eye, but also in numerous extraocular tissues. At an ocular level, there is atrophy of the iris dilator muscle fibre cells, degeneration of the irideal pigment with dispersion of melanin, peripupillar atrophy and an increase in the trabecular meshwork pigmentation. A typical feature is the excessive accumulation of the extracellular matrix material in the juxtacanalicular tissue. This accumulation explains the increased resistance to aqueous outflow found in eyes with PEXG.

#### Study aim:

To assess the variations in the metalloproteinases (MMP-2) and tissue inhibitor of metalloproteinases (TIMP-2) values following selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG).

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Ethics approval received from the Institutional Ethics Committee of the St Orsola Malpighi University Hospital, University of Bologna on the 24th October 2007 (ref: 2007-007744-98).

#### Study design

Observational, open, single centre, case-control study

#### Primary study design

Observational

# Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Pseudoexfoliative secondary glaucoma

#### **Interventions**

Arm 1: Patients with pseudoexfoliative glaucoma with good intraocular eye pressure (IOP) control and cataract (15 patients). These patients received cataract surgery only. Arm 2: Patients with pseudoexfoliative glaucoma only that undewent selective laser trabeculoplasy (SLT) without good control of IOP (15 patients). These patients received SLT, and after one month surgical trabeculectomy.

Arm 3 (control group): Patients with catarct only (15 patients). These patients received catarct surgery only.

Selective laser trabeculoplasty (SLT) was performed with Selecta 7000 (Q switched, frequency doubled, 532 Nd:YAG laser) using 50 non-overlapping applications in the inferior 180° of the trabecular meshwork, with a spot size of 400 µm and pulse duration of 3 ns. Aqueous humour was aspirated during surgery from patients.

#### Intervention Type

Other

#### Phase

**Not Specified** 

### Primary outcome(s)

MMP-2 and TIMP-2 concentration, assessed once during the cataract surgery in Arm 1 and 3, and during trabeculectomy in Arm 2.

## Key secondary outcome(s))

Intraocular pressure, measured before surgery and 7, 15 days and one month after surgery in all three arms of participants.

#### Completion date

15/06/2006

# Eligibility

#### Key inclusion criteria

Fifteen patients with pseudoexfoliative glaucoma and cataract, and 15 patients with pseudoexfoliative glaucoma (30 patients in total):

- 1. Patients of either gender
- 2. Aged from 58 74 (in all three arms)

#### Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

Adult

#### Sex

All

#### Total final enrolment

30

#### Key exclusion criteria

- 1. Pseudophachia
- 2. Non-pseudoexfoliative glaucoma
- 3. History of laser treatment

#### Date of first enrolment

13/02/2006

#### Date of final enrolment

15/06/2006

# Locations

#### Countries of recruitment

Italv

Study participating centre Via Massarenti, 9 Bologna Italy 40138

# Sponsor information

## Organisation

University of Bologna (Italy)

#### **ROR**

https://ror.org/01111rn36

# Funder(s)

## Funder type

Hospital/treatment centre

#### **Funder Name**

St Orsola Malpighi University Hospital Bologna (Italy)

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	21/10/2008	30/12/2020	Yes	No